Last reviewed · How we verify
Rapidly Cycled HAART
Rapidly Cycled HAART is a highly active antiretroviral therapy regimen that uses rapid rotation or cycling of different antiretroviral drug classes to suppress HIV replication and potentially reduce resistance development.
Rapidly Cycled HAART is a highly active antiretroviral therapy regimen that uses rapid rotation or cycling of different antiretroviral drug classes to suppress HIV replication and potentially reduce resistance development. Used for HIV-1 infection.
At a glance
| Generic name | Rapidly Cycled HAART |
|---|---|
| Sponsor | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
| Drug class | Antiretroviral therapy regimen (combination therapy) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
This approach involves alternating between different combinations of antiretroviral drugs (typically nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors) on a scheduled basis rather than using a fixed combination continuously. The rationale is that rapid cycling may prevent the emergence of drug-resistant viral strains by not allowing any single resistant mutant population to become dominant, while maintaining viral suppression.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Lipodystrophy
- Hepatotoxicity
- Peripheral neuropathy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: